Dashboard
Manage Tickers

ACST


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

acasti-pharma-q3-eps-021-up-from-052-yoy
Acasti Pharma Q3 EPS $(0.21) Up From $(0.5...
02/12/2024 13:12:22

Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0...

craig-hallum-initiates-coverage-on-acasti-pharma-with-buy-rating-announces-price-target-of-6
Craig-Hallum Initiates Coverage On Acasti ...
02/07/2024 14:10:43

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces P...

acasti-announces-poster-detailing-gtx-104-strive-on-trial
Acasti Announces Poster Detailing GTX-104 ...
02/01/2024 13:39:22

The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhag...

why-keycorp-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why KeyCorp Shares Are Trading Lower By Ov...
01/18/2024 18:08:48

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results...

acasti-announces-dosing-of-first-patient-in-gtx-104-strive-on-trial
Acasti Announces Dosing Of First Patient I...
10/23/2023 12:05:38

acasti-pharma-inc-files-for-shelf-of-up-to-66m-common-shares-by-selling-stockholders
Acasti Pharma Inc Files For Shelf Of Up To...
10/06/2023 20:36:42

-SEC Filing

acasti-pharma-10-owner-vimal--kavuru-reported-purchase-of-1099103-shares--avg-price-of-119share-in-form-4-filing-on-wednesday
Acasti Pharma 10% Owner Vimal Kavuru Repo...
09/28/2023 09:22:52

why-td-synnex-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why TD SYNNEX Shares Are Trading Lower By ...
09/26/2023 16:56:35

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results...

why-acasti-pharma-acst-stock-is-exploding-higher
Why Acasti Pharma (ACST) Stock Is Explodin...
09/26/2023 14:57:29

Acasti Pharma Inc (NASDAQ: ACST) shares are trading higher by 34.3% to $2.35 Tuesday morning after the company announced $7.5 m...

acasti-announces-75m-private-placement-equity-financing
Acasti Announces $7.5M Private Placement E...
09/26/2023 12:01:35

acasti-to-present-gtx-104-pharmacokinetic-comparison-data-at-neurocritical-care-annual-meeting
Acasti To Present GTX-104 Pharmacokinetic ...
08/09/2023 21:23:29

Acasti Pharma Inc. (NASDAQ:ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104...

acasti-announces-wuxi-clinical-as-cro-to-conduct-strive-on-phase-3-safety-trial-for-gtx-104-in-asah-patients
Acasti Announces WuXi Clinical As CRO To C...
07/10/2023 13:08:46

STRIVE-ON is a pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nim...

acasti-pharma-announces-1-for-6-reverse-stock-split
Acasti Pharma Announces 1-For-6 Reverse St...
07/07/2023 12:03:17

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104...

why-1847-holdings-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why 1847 Holdings Shares Are Trading Lower...
07/05/2023 17:28:59

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from ...

acasti-announces-alignment-with-fda-on-gtx-104-pivotal-phase-3-safety-trial-protocol-and-confirms-planned-initiation-of-strive-on-in-asah-patients-in-calendar-q4-2023
Acasti Announces Alignment With FDA On GTX...
07/05/2023 13:03:26

update-acasti-pharma-q4-adj-eps-011-inline
UPDATE: Acasti Pharma Q4 Adj EPS $(0.11), ...
06/23/2023 12:33:42

Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a ...

recap-acasti-pharma-q4-earnings
Recap: Acasti Pharma Q4 Earnings
06/23/2023 12:20:07

acasti-pharma-q4-adj-eps-011-inline-cash-balance-of-279m
Acasti Pharma Q4 Adj EPS $(0.11), Inline, ...
06/23/2023 11:47:01

Acasti Pharma (NASDAQ: ACST) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a...

fda-has-allowed-acasti-pharma-to-proceed-with-the-initiation-of-gtx-104-phase-3-safety-clinical-trial-in-aneurysmal-subarachnoid-hemorrhage-patients
FDA Has Allowed Acasti Pharma To Proceed W...
04/04/2023 12:09:07

The FDA concurred with the suitability of the 505(b)(2) regulatory pathway with the selected Reference Listed Drug (RLD) Nimoto...

ef-hutton-reiterates-buy-on-acasti-pharma-maintains-25-price-target
EF Hutton Reiterates Buy on Acasti Pharma,...
02/15/2023 12:02:38

EF Hutton analyst Constantine Davides reiterates Acasti Pharma (NASDAQ:ACST) with a Buy and maintains $2.5 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION